EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

[ 18 F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [ 18 F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status

Joanna K Weeks, Austin R Pantel, Sarah B Gitto, Fang Liu, Erin K Schubert, Daniel A Pryma, Michael D Farwell, David A Mankoff, Robert H Mach, Fiona Simpkins, Lilie L Lin

Journal of Nuclear Medicine · 2025-01 · 66 (1) · 34-39

DOI: 10.2967/jnumed.124.267627 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 05.12.2024. Verfasst von Joanna K Weeks und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Interventional Radiology, Department of Radiology, Weill Cornell Medicine, New York, New York. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Ovarian Neoplasms, Mutation, Positron-Emission Tomography. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly(adenosine diphosphate-ribose) polymerase-1 (PARP1) inhibitors have improved ovarian cancer treatment outcomes. However, clinical response remains heterogeneous. Existing biomarkers, mainly breast cancer susceptibility genes 1 and 2 (BRCA1/2), are suboptimal. New tools are needed to guide patient selection. In this study, [18F]fluorthanatrace ([18F]FTT), a PET radiotracer for imaging PARP1, was compared with [18F]FDG and tumor features commonly assessed in ovarian cancer.

Methods

Subjects with epithelial ovarian cancer underwent both [18F]FTT and [18F]FDG PET before new oncologic treatment. The SUVmax of [18F]FTT and [18F]FDG was compared between lesions. [18F]FTT SUVmax was compared with tumor location, tumor grade, and germline or somatic BRCA1/2 status. Linear mixed models were fitted to identify subject-level differences.

Results

Fifty-five lesions were identified in 14 subjects. No correlation was found between [18F]FTT SUVmax and [18F]FDG SUVmax per lesion, supporting distinct molecular targets. [18F]FTT uptake varied widely across lesions, with no significant differences between mean SUVmax and tumor location, grade, or BRCA1/2 status.

Conclusion

Our findings suggest that [18F]FTT PET may provide unique information on ovarian cancer distinct from [18F]FDG PET and commonly assessed tumor features. Our results imply a wide range of PARP1 expression in the studied ovarian tumors not explained by [18F]FDG PET, location, grade, or mutational status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Ovarian NeoplasmsMutationPositron-Emission TomographyNeoplasm GradingHumansFemaleMiddle AgedAgedAdultBreast Neoplasms

Stichwörter der Autor:innen

BRCAPARP1[18F]FTT[18F]fluorthanatraceovarian cancer

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Division of Interventional Radiology, Department of Radiology, Weill Cornell Medicine, New York, New York.
  • Division of Nuclear Medicine Imaging and Therapy, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; and.
  • Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas lllin@mdanderson.org.

Förderung

  • NCI NIH HHS

Zitieren

APA

Weeks, J. K., Pantel, A. R., Gitto, S. B., Liu, F., Schubert, E. K., Pryma, D. A., Farwell, M. D., Mankoff, D. A., Mach, R. H., Simpkins, F., & Lin, L. L. (2025). [ 18 F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [ 18 F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status. Journal of Nuclear Medicine, 66(1), 34-39. https://doi.org/10.2967/jnumed.124.267627

Vancouver

Weeks JK, Pantel AR, Gitto SB, Liu F, Schubert EK, Pryma DA, et al. [ 18 F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [ 18 F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status. Journal of Nuclear Medicine. 2025;66(1):34-39. doi:10.2967/jnumed.124.267627

BibTeX
@article{Weeks2025,
  author = {Weeks, Joanna K and Pantel, Austin R and Gitto, Sarah B and Liu, Fang and Schubert, Erin K and Pryma, Daniel A and Farwell, Michael D and Mankoff, David A and Mach, Robert H and Simpkins, Fiona and Lin, Lilie L},
  title = {[ 18 F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [ 18 F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {1},
  pages = {34--39},
  doi = {10.2967/jnumed.124.267627}
}
Kostenlos starten →